LongBio Pharma closed its Hong Kong IPO on June 2 with a 4,470-fold oversubscription, setting a recent market record. The clinical-stage company, whic…

LongBio Pharma closed its Hong Kong IPO on June 2 with a 4,470-fold oversubscription, setting a recent market record. The clinical-stage company, whic…

China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange